Table 4.

ASFV subunit vaccines tested in vivo that induced some level of protection

Gene Name	Immunization	Challenge strain	Outcome	Haplotype	Reference
A179L, B407L, B438L, B602L, B646L, Complement (183875–184,183), CP204L, CP2475L, CP530R, D117L, D339L, DP71L, E120R, E183L, E199L, EP153R, EP364R, EP402R, F1055L, F317L, G1211R, G1340L, H108R, I329L, K205R, KP177R, L10L, M1249L, MGF110-2 L, MGF110-4 L, MGF300-2R, MGF360-11 L, MGF360-15R, MGF360-18R, MGF360-1 L, MGF505-4R, MGF505-5R, NP1450L, NP419L & O61R	DNA prime + rVACV boost	Georgia 2007/1	No surviving pigs Reduced viremia and viral loads in some tissues	Babraham	[73]
B646L, CP204L, CP2475L (p37, p150), CP530R & E183L	rAd	Georgia 2007/1	Partial protection: 5/9 surviving pigs versus 1/5 control pigs Reduced viremia depending on the adjuvant used Pigs recover from infection Authors claim that none of the immunogens conferred statistically significant protection	Outbred	[71, 81]
A151R, B646L, C129R, CP204L, CP530R, E146L, I215L, I73R, L8L, M448R, MGF110-4 L & MGF110-5 L	rAd prime + MVA boost	OUR T88/1	No surviving pigs 3/6 pigs with reduced and delayed clinical signs, 5/6 pigs with reduced viremia Reduced viral load in some tissues	Outbred	[38]
CP2475L & A137R	Synthetic peptides	E70	No surviving pigs Increased average survival Reduced mean viral titers	Outbred	[72]
CP204L & B646L	Synthetic peptides	E70	No surviving pigs Increased average survival Reduced mean viral titers	Outbred	[72]
CP204L, E183L & EP402	DNA (as a fusion with Ub)	E75	Partial protection: 2/6 surviving pis Delayed clinical signs and viremia Pigs recover from the infection	Outbred	[89]
CP312R	DNA expression library	E75	Partial protection: 6/10 surviving pigs Reduced virus titers in blood, shedding and lesions Pigs recover from the infection	Outbred	[91, 94]